Catalyst
Slingshot members are tracking this event:
Verastem (VSTM) expects to report top-line data from the Phase 3 DUO Study of duvelisib/ofatumumab infusions in Relapsed or Refractory CLL in mid-year 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VSTM | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2017
Occurred Source:
http://www.businesswire.com/news/home/20170906005599/en/Verastem-Announces-Positive-Top-line-Data-Pivotal-Phase
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Interim Analysis, Duvelisib, Duo Trial, Relappsed/refractory Chronic Lymphocytic Leuk, Cll
